We are proud to have helped CCMC launch and sustain its innovative Adolescent & Young Adult Cancer Program.  Under leadership of its Director, Micheal Isakoff, MD, the Program is expanding the availability of clinical trials to cancer patients ages 15-40.  This demographic has been underserved by clinical trials, the mechanism which explores the effectiveness and safety of new antineoplastic agents and new combination therapies.  Without access to clinical trials, the AYA cancer population has little hope that better treatments will be identified.

The AYA Cancer Program at CCMC Includes a multidisciplinary team including specialists in oncology, general surgery, orthopedic surgical oncology, radiation oncology, nurses, social workers, a consulting psychologist, radiologists, and patient life specialists. The program treats patients with a wide range of cancer diagnoses including Leukemia, Hodgkin's and non-Hodgkin's lymphoma, soft tissue and bone sarcomas, brain tumors, and germ cell tumors.

Dr. Michael Isakoff leads the AYA Cancer Program and has a special expertise in bone and soft tissue sarcomas. Consultations with patients occur in the outpatient clinic at CCMC and in the inpatients settings at CCMC along with regional adult care hospitals for patients less than age 40, including at UCONN Health Center and St. Francis Hospital. 

Each patient's physician participates in the coordination of care and medical decision-making discussions with parents and patients. When appropriate, patients who are eligible are given an opportunity to enroll on a clinical trial.